Endothelial Dysfunction Clinical Trial
Official title:
The Effects of Watermelon Juice Supplementation on Postprandial Vascular Endothelial Function and Blood Flow During Hyperglycemia: A Pilot Study
The purpose of this study is to test if watermelon juice supplementation improves vascular dysfunction experience during hyperglycemia.
The objective of this pilot study is to determine the potential for watermelon juice to
attenuate the reduction postprandial endothelial function and skeletal muscle microvascular
blood flow (MVBF) experienced during hyperglycemia.
We will attempt to answer the following hypotheses:
Hypothesis 1: Watermelon juice supplementation will attenuate the reduction in endothelial
dysfunction and microvascular blood flow during an oral glucose challenge.
Hypothesis 2: Watermelon juice will increase L-arginine bioavailability during hyperglycemia
and correlate with improved vascular response.
Exploratory Aim: The postprandial period is defined by increased sympathetic nervous system
activity (vasoconstriction) and NO• mediated vasodilation. Heart rate variability (HRV) is a
measurement of the balance of parasympathetic to sympathetic activity. We will measure HRV
during the oral glucose challenge to interrogate the possibility that watermelon juice can
modulate the balance of blood vessel constriction and relaxation during an oral glucose
Procedures Involved
There will be 1 screening visit, and 2 outpatient visits. Participants will consume
watermelon juice or placebo for 2 weeks. The washout period will last 2 weeks prior to the
cross-over to the opposite condition. Participants visits will be conducted at the Vascular
and Resting Metabolism Lab located in the department of kinesiology at LSU.
Screening Visit
Participants will undergo consenting and fasting blood draws to measure glucose, lipids, and
CBC. Vital signs (blood pressure, body weight, body composition (DXA), heart rate, etc) will
be measured. For DXA procedure participants will undergo a whole body scan lasting
approximately 10 minutes. Participants will remove all metal objects from their body and lie
down on the table. The legs will be secured together using two Velcro straps. The participant
will be instructed to remain completely still during the scan. Randomization will be
performed to allocate the study participant for their initial group assignment to either the
watermelon juice group or placebo. The initial six participants will be assigned treatment A
for phase 1 and treatment B for phase 2, thereafter the following 6 will be assigned
treatment B first then treatment A. The remaining participant will be randomly assigned
either treatment A or B in a counterbalanced fashion.
Daily Juice Drop-in visits
Since the required supplementation duration is 14 days participants will be provided with 2
days (Saturday and Sunday) worth of watermelon juice or placebo to account for days when the
LSU AG Center will not be open. To allow for scheduling conflicts and unforeseen
circumstances a 3 day period of supplementation less then or greater than the 14 periods will
be permitted. Participants will also be provided with juice or placebo for anticipated
instances where they cannot be on campus. In order to monitor compliance participants will be
asked return the juice container for the days where juice was consumed off premises.
Visit 2 and 3: Oral Glucose Challenge - Postprandial FMD and MVBF
Participants will arrive in morning at 6:00am fasted for 10-hours. Body composition will be
measured by DXA. Next, participants will rest for 30 minutes in the supine positing while
wearing a heart rate monitor (Zephyr, Bioharness) to measure heart rate and heart rate
variability. Resting metabolic rate will be measured via indirect calorimetry for 20 minutes.
Then fasting measures of blood glucose, FMD (ultrasound) and MVBF (near-infrared
spectroscopy) will be taken followed by ingestion of 75 g of glucose (glucola). An IV line
will be placed in the participants arm vein for blood draw purposes and will remain there
throughout the testing. A blood sample will be drawn, and then the participant will drink a
sugar solution consisting of 75 grams of glucose. Blood will be drawn at specific times after
you consume the drink. Each blood sample will be about 1 tablespoon. (6 tablespoons total for
the test). During the IV procedure, a small amount of the participant's own blood (less than
1 teaspoon) will immediately be returned into your vein through the IV after each specimen is
collected. Blood will be drawn at minute 15, 30, 60, 90, 120 minutes. Postprandial
measurements of FMD and MVBF will be taken at 30, 60, 90, and 120 minutes.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02122198 -
Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women
|
N/A | |
Completed |
NCT04156711 -
Remote Ischemic Preconditioning in Patients Undergoing Acute Minor Abdominal Surgery
|
N/A | |
Recruiting |
NCT06133634 -
Fisetin to Improve Vascular Function in Older Adults
|
Phase 1/Phase 2 | |
Completed |
NCT05872139 -
Role of Mitochondrial-derived Oxidative Stress to Promote Vascular Endothelial Dysfunction in Non-exercisers With Aging
|
N/A | |
Recruiting |
NCT04558450 -
Covid-19 Effects on Arterial Stiffness and Vascular Aging (CARTESIAN)
|
N/A | |
Terminated |
NCT03325933 -
Resistance Training and Cardiometabolic Health
|
N/A | |
Not yet recruiting |
NCT05939934 -
Impact of the Mandibular Advancement Device on Sleep Apnea During CPAP Withdrawal
|
N/A | |
Completed |
NCT02652975 -
Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium
|
N/A | |
Recruiting |
NCT02334839 -
The Association Between Severity of Hypertensive Disorder During Pregnancy and Endothelial Dysfunction
|
N/A | |
Recruiting |
NCT02020044 -
Outcome After Descemet Membrane Endothelial Keratoplasty (DMEK) and Ultra-thin Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)
|
N/A | |
Completed |
NCT01691404 -
Study on the Effects of Epicatechin and Quercetin Supplementation on Vascular Function and Blood Pressure (FLAVO)
|
N/A | |
Completed |
NCT01775865 -
Targeting Inflammation to Treat Cardiovascular Aging
|
Phase 2 | |
Terminated |
NCT01412216 -
The Effects of Sedentarism on Vascular Function, Inflammation, and Insulin Resistance
|
Phase 2 | |
Completed |
NCT01319344 -
Effect of Eplerenone on Endothelial Function in Metabolic Syndrome
|
Phase 3 | |
Completed |
NCT00848302 -
Endothelial Function in Human Arteries
|
Early Phase 1 | |
Completed |
NCT00990730 -
Atherosclerosis in Rheumatoid Arthritis
|
N/A | |
Completed |
NCT00987974 -
Short Term Statin Treatment and Endothelial Dysfunction Due to Ischemia and Reperfusion Injury
|
Phase 4 | |
Completed |
NCT00532844 -
A Phase 2, Pharmacokinetic (PK) Study of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction
|
Phase 2 | |
Completed |
NCT00376246 -
Effect of Ezetimibe on Flow-mediated Brachial Artery Reactivity in Healthy Subjects
|
Phase 4 | |
Completed |
NCT00775099 -
Combustion Derived Air Pollution and Vascular Function
|
N/A |